Lucentis (ranibizumab) / Roche, Novartis, Santen, China Medical System - LARVOL DELTA

A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD) (clinicaltrials.gov) - P3 | N=443 | Completed | Sponsor: Jecho Biopharmaceuticals Co., Ltd.

New P3 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Efficacy and safety of switching from Eylea® and Lucentis® to Ranivisio® in exudative age-related macular degeneration and its impact on treatment costs (PubMed, J Fr Ophtalmol) - "Switching from Eylea® and Lucentis® to Ranivisio® is effective in exudative AMD, with a good safety profile, and could help to reduce treatment costs."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Safety and tolerability of avacincaptad pegol in combination with ranibizumab in treatment-naïve patients with neovascular age-related macular degeneration: results from a phase 1 and phase 2a study. (PubMed, BMJ Open Ophthalmol) - P1, P2 | "Coadministration of ACP and ranibizumab in treatment-naïve patients with nAMD was well tolerated across different dosing regimens with no new safety issues based on results from two independent studies."

Clinical • Journal • P1 data • P2a data • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Radiotherapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. (PubMed, Curr Eye Res) - "For SRT combined with anti-VEGF therapy, there was a greater risk of losing more than 15 ETDRS letters at 24 months (RR 1.75, 95% CI 1.12-2.74) compared with anti-VEGF monotherapy; however, the SRT group required 2.10 fewer ranibizumab injections than the sham-irradiation group (mean difference [MD] -2.10, 95% CI -2.97 to -1.22). Epimacular brachytherapy (EBM) combined with anti-VEGF therapy may worsen patient outcomes and increase the risk of adverse events. In contrast, stereotactic radiotherapy (SRT) combined with anti-VEGF therapy does not improve visual acuity but can reduce the frequency of anti-VEGF injections, potentially alleviating the treatment burden for patients with nAMD."

Journal • Retrospective data • Review • Age-related Macular Degeneration • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A single-arm, phase II clinical study of Sacituzumab Tirumotecan combined with Bevacizumab for the treatment of platinum-resistant epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer (ChiCTR) - P2 | N=30 | Not yet recruiting | Sponsor: Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

New P2 trial • Platinum resistant • Epithelial Ovarian Cancer • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor

Choroidal Neovascularization and Extensive Macular Atrophy With Pseudodrusen: a Retrospective Comparative Case Series. (PubMed, J Vitreoretin Dis) - "Treatments included aflibercept (7 eyes), ranibizumab (1 eye), and 1 eye treated with combination therapy with aflibercept, ranibizumab, and faricimab (mean 8 injections/eye); 3 eyes had incomplete treatment information and 3 eyes did not receive treatment. Early CNV diagnosis is crucial for timely treatment initiation, aiming to optimize anatomic and functional outcomes. While visual responses varied, our findings indicate that anti-VEGF therapy plays a significant role in stabilizing or improving vision."

Journal • Retrospective data • Age-related Macular Degeneration • Dry Age-related Macular Degeneration

Short-Term Results of Dexamethasone Intravitreal Implant in Patients with Persistent Diabetic Macular Edema. (PubMed, Niger J Clin Pract) - "IVDI demonstrated substantial enhancement in patients with chronic persistent DME who were resistant to different treatments, with peak efficacy observed in the second month. Therefore, it may be considered an alternative therapeutic choice."

Journal • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Comparison of the Effects of Biosimilar QL1205 and Lucentis® on OCTA and Aqueous Humor Biomarkers in Patients with Macular Edema due to Retinal Vein Occlusion (ChiCTR) - P4 | N=60 | Not yet recruiting | Sponsor: Bengbu Municipal Second People Hospital; Bengbu Municipal Second People Hospital

New P4 trial • Macular Edema • Ophthalmology • Retinal Vein Occlusion

Observation on the Efficacy of Ranibizumab Injection with 3+PRN Regimen Combined with PRP in the Treatment of DME (ChiCTR) - P4 | N=90 | Not yet recruiting | Sponsor: Qilu Hospital of Shandong University; Qilu Hospital of Shandong University

New P4 trial • Diabetic Macular Edema • Ophthalmology

Regional association between PM2.5 exposure and anti-VEGF treatment demand for age-related macular degeneration: a nationwide ecological study in Japan. (PubMed, Environ Sci Pollut Res Int) - "This nationwide analysis revealed a significant association between regional PM2.5 levels and the use of anti-VEGF intravitreal injections for macular diseases. No such relationship was observed for SOX, NOX, or PMD. These findings suggest that PM2.5 may contribute to the regional demand for AMD treatment, highlighting the need for further investigation into the impact of air pollution on ocular health."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Fluorescence lifetime imaging ophthalmoscopy (FLIO) of patients with neovascular age-related macular degeneration before and after treatment with intravitreal ranibizumab. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "FLIO parameters correlated with visual acuity changes, while retinal thickness did not. This suggests that FLIO may capture treatment-induced alterations beyond structural changes, potentially reflecting metabolic processes. FLIO may therefore serve as a valuable adjunct tool for monitoring anti-VEGF therapy response in neovascular AMD."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Adjunctive Intravitreal moxifloxacin and ranibizumab in the Management of Intraocular Tuberculoma. (PubMed, Retin Cases Brief Rep) - "Adjunctive intravitreal moxifloxacin and ranibizumab, when combined with systemic ATT and corticosteroids, appears to be a valuable therapeutic option in the management of intraocular tuberculoma, especially in cases with macular involvement. Tailored local therapy based on clinical phenotype may enhance lesion control and reduce systemic treatment duration."

Journal • Cataract • Glaucoma • Ocular Inflammation • Ophthalmology • Uveitis

Subjective Changes in Vision of Patients with Diabetic Macular Edema Treated with Ranibizumab. (PubMed, Cesk Slov Oftalmol) - " We determined that anti-VEGF ranibizumab treatment improved objective parameters after one year of intravitreal therapy in LS, CRT and TMV. Subjective changes in visual perception improved in all the monitored parameters after one year of treatment."

Journal • Diabetic Macular Edema • Ophthalmology • Pain

VFQ-25 With and Without Rasch Scoring Assessed Using Simulated Data in Trials Comparing Laser With Anti-VEGF for Diabetic Retinopathy. (PubMed, Transl Vis Sci Technol) - "We simulated 10,000 randomized controlled trials (RCTs), using random sample-and-replace bootstrapping methods from open-source data obtained from individual patient VA and National Eye Institute Visual Function Questionnaire-25 (VFQ-25) responses in the Diabetic Retinopathy Clinical Research (DRCR) Retina Network Protocol S, comparing ranibizumab with panretinal photocoagulation for proliferative diabetic retinopathy...Treatment group differences in Rasch calibrated VFQ-25 domains (visual function, socioemotional, combined) had the highest correlation with differences in VA, although the original multidimensional non-Rasch composite and near activities were similar. Use of Rasch calibrated scores is recommended for desirable psychometrics, but it may be acceptable to use the raw scored original composite instrument."

Clinical • Journal • Diabetic Retinopathy • Retinal Disorders

The Effect of Intravitreal Ranibizumab Injection on Retinal Nerve Fiber Layer Thickness and Optic Disc Parameters. (PubMed, J Clin Med) - "Given the absence of untreated control eyes and the exclusion of patients with glaucoma, these findings apply only to non-glaucomatous eyes and should not be extrapolated to patients with glaucoma. Further prospective studies with larger cohorts, appropriate control groups, and longer follow-up durations are warranted to clarify the long-term effects of anti-VEGF therapy on the optic nerve."

Journal • Age-related Macular Degeneration • Diabetic Macular Edema • Glaucoma • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

U.S. trends of anti-vascular endothelial growth factor use from 2017-2023: An analysis of medicare, medicaid, and commercial insurance. (PubMed, PLoS One) - "Aflibercept 2 mg was the most common drug used overall from 2017-2023. Faricimab had the highest absolute and relative increase in utilization from 2022-2023. Patients with Medicare B or C were significantly more likely to receive aflibercept over bevacizumab."

Journal • Medicare • Reimbursement • Retrospective data • US reimbursement • Ophthalmology

BURGUNDY: Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=177 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Dec 2028 ➔ Aug 2026 | Trial primary completion date: Feb 2027 ➔ Aug 2026 | Recruiting ➔ Active, not recruiting

Enrollment closed • First-in-human • Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Infographic: Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW and RAINBOW Extension Study). (PubMed, Eye (Lond)) - No abstract available

Journal • Retinal Disorders • Retinopathy of Prematurity

Effectiveness of aflibercept, ranibizumab, and Ozurdex for treating diabetic macular edema showing a suboptimal response: A comparative observational study. (PubMed, Taiwan J Ophthalmol) - "Resistance to anti-VEGF occurs in a substantial proportion of patients with DME. Few studies compare the efficacy of anti-VEGF agents and steroid therapy as second-line treatment for DME to determine the best treatment strategy. Injections of the examined drugs provide a similar clinical benefit. The increase in IOP following steroid injections compared to anti-VEGF agents is well known and has been previously described. It should be well considered before selecting second-line treatment."

Journal • Observational data • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders

Ranibizumab on optic disc perfusion in central retinal vein occlusion. (PubMed, Int J Ophthalmol) - "Optic disc blood perfusion is more closely associated with visual acuity than macular perfusion, suggesting intra-disc VD may serve as a potential biomarker for monitoring visual acuity changes in CRVO. Multiple ranibizumab injections significantly improve optic disc perfusion but may have exerted detrimental effects on the macula. CRVO patients shows higher hemorheological parameters than those with normal fundi. Reduced vertical C/D ratio and optic cup volume may be linked to CRVO incidence, potentially acting as susceptibility factors."

Journal • Diabetic Retinopathy • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

Successful Cataract Surgery in a Patient with a Port Delivery System Implant for Diabetic Macular Edema. (PubMed, Case Rep Ophthalmol) - "The Port Delivery Platform (PDS) with ranibizumab is a novel, surgically implanted device designed for continuous intraocular anti-VEGF delivery, approved for neovascular age-related macular degeneration and other retinal vascular diseases, including diabetic macular edema (DME) and diabetic retinopathy. This case highlights key surgical considerations to preserve implant integrity and conjunctival health during cataract surgery in eyes with PDS implants. To our knowledge, this is the first report of cataract surgery in a PDS-implanted eye outside a clinical trial, emphasizing that standard phacoemulsification techniques can be safely adapted with proper precautions in this context."

Journal • Age-related Macular Degeneration • Cardiovascular • Cataract • Diabetic Macular Edema • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

BAROLO: A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME (clinicaltrials.gov) - P2/3 | N=1054 | Active, not recruiting | Sponsor: EyeBiotech Ltd. | Trial completion date: Jun 2028 ➔ Mar 2028 | Trial primary completion date: Jun 2028 ➔ Mar 2027

Trial completion date • Trial primary completion date • Diabetic Macular Edema • Ophthalmology

Intravitreal Ranibizumab Injections Significantly Influence Retinal Venous Calibre in Patients With Diabetic Macular Oedema. (PubMed, J Ophthalmol) - "Ranibizumab treatment was associated with a significant reduction in CRVE and increase in AVR. It is possible that the positive effect of ranibizumab therapy on improvements in BCVA and CMT may be related to reduction of retinal venous calibre and hydrostatic pressure."

Journal • Diabetic Macular Edema • Macular Edema • Ophthalmology

Cost-effectiveness analysis of early versus late switching in treatment-naïve patients with refractory diabetic macular oedema in the Turkish population: real-world data from the Bosphorus DME study group, report number 5. (PubMed, Clin Exp Optom) - "The aim of this work is to evaluate the cost-effectiveness of early versus late switching to intravitreal aflibercept or ranibizumab in eyes with DME refractory to intravitreal bevacizumab loading treatment...Late switching produced limited benefit at high cost, rendering it an unfavourable option. Treatment decisions should balance clinical efficacy and cost-effectiveness on an individual basis."

HEOR • Journal • Real-world evidence • Diabetic Macular Edema • Macular Edema • Ophthalmology

Anti-VEGF Therapy Switching in Neovascular Age-Related Macular Degeneration: Insights from Automated Volumetric Retinal Fluid Analysis. (PubMed, Retina) - "Automated fluid analysis reliably quantifies treatment response in nAMD. Early switchers showed worsening after bevacizumab, while late switchers had partial responses. These findings highlight the potential of automated analysis to support more individualized, data-driven treatment strategies. Prospective studies are required to confirm impact on patient outcomes."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration